Title |
Cytotoxic activity evaluation and QSAR study of chromene-based chalcones
|
---|---|
Published in |
Archives of Pharmacal Research, December 2012
|
DOI | 10.1007/s12272-012-1208-2 |
Pubmed ID | |
Authors |
Loghman Firoozpour, Najmeh Edraki, Maryam Nakhjiri, Saeed Emami, Maliheh Safavi, Sussan Kabudanian Ardestani, Mehdi Khoshneviszadeh, Abbas Shafiee, Alireza Foroumadi |
Abstract |
Chalcone and chromene motifs are synthetic or naturally occurring scaffolds with significant cytotoxic profile. Two types of novel regioisomeric chromene-chalcone hybrids, namely 1-(6-chloro or 6-methoxy-2H-chromen-3-yl)-3-phenylprop-2-en-1-one (Type A) and 3-(6-chloro or 6-methoxy-2H-chromen-3-yl)-1-phenylprop-2-en-1-one (Type B), both with different substituents on the phenyl ring attached to propenone linkage, have been evaluated for their cytotoxic activity against breast cancer cell lines (MCF-7 and MDA-MB-231). The results indicate that type A of chromene-chalcones demonstrated better cytotoxic profile than type B especially in MDA-MB-231 cell line. In addition, the growth inhibitory activity of most of the target compounds is higher than Etoposide as a reference drug. QSAR analysis of these novel compounds demonstrated that topological and geometrical parameters are among the important descriptors that influence the cytotoxic activity profile of compounds. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 32 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 16% |
Student > Doctoral Student | 5 | 16% |
Professor | 3 | 9% |
Student > Ph. D. Student | 3 | 9% |
Researcher | 2 | 6% |
Other | 6 | 19% |
Unknown | 8 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 9 | 28% |
Biochemistry, Genetics and Molecular Biology | 5 | 16% |
Agricultural and Biological Sciences | 3 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
Medicine and Dentistry | 3 | 9% |
Other | 1 | 3% |
Unknown | 8 | 25% |